Article
KIR2DS1 genotype predicts for complete cytogenetic response and survival in newly diagnosed chronic myeloid leukemia patients treated with imatinib.
Leukemia - 1 Feb 2012
Marin D, Gabriel I H, Ahmad S, Foroni L, de Lavallade H, Clark R, O'Brien S, Sergeant R, Hedgley C, Milojkovic D, Khorashad J S, Bua M, Alsuliman A, Khoder A, Stringaris K, Cooper N, Davis J, Goldman J M, Apperley J F, Rezvani K
Abstract excerpt
Natural killer (NK) cells are expanded in chronic myeloid leukemia (CML) patients on tyrosine kinase inhibitors (TKI) and exert cytotoxicity. The inherited repertoire of killer immunoglobulin-like receptors (KIR) may influence response to TKI. We investigated the impact of KIR-genotype on outcome in 166 chronic phase CML patients on first-line imatinib treatment. We validated our findings in an independent...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.